Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “add” rating reaffirmed by stock analysts at Numis Securities Ltd in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. They presently have a GBX 1,560 ($20.32) price target on the stock. Numis Securities Ltd’s price objective suggests a potential upside of 21.31% from the stock’s current price.
HIK has been the subject of several other reports. Jefferies Group LLC reduced their target price on Hikma Pharmaceuticals Plc from GBX 1,450 ($18.88) to GBX 1,390 ($18.10) and set an “underweight” rating for the company in a research note on Wednesday, June 28th. HSBC Holdings plc reduced their target price on Hikma Pharmaceuticals Plc from GBX 1,700 ($22.14) to GBX 1,410 ($18.36) and set a “reduce” rating for the company in a research note on Tuesday, June 27th. Citigroup Inc. restated a “neutral” rating and issued a GBX 1,550 ($20.18) target price on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, June 28th. Morgan Stanley downgraded Hikma Pharmaceuticals Plc to an “equal weight” rating and reduced their target price for the company from GBX 2,050 ($26.70) to GBX 1,600 ($20.84) in a research note on Wednesday, August 2nd. Finally, J P Morgan Chase & Co restated a “neutral” rating and issued a GBX 1,500 ($19.53) target price on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, June 27th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of GBX 1,892.10 ($24.64).
Shares of Hikma Pharmaceuticals Plc (HIK) opened at 1286.00 on Friday. The company’s market cap is GBX 3.10 billion. Hikma Pharmaceuticals Plc has a 12-month low of GBX 1,277.00 and a 12-month high of GBX 2,354.00. The company has a 50-day moving average price of GBX 1,412.94 and a 200-day moving average price of GBX 1,776.73.
ILLEGAL ACTIVITY WARNING: “Hikma Pharmaceuticals Plc (LON:HIK) Rating Reiterated by Numis Securities Ltd” was published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://transcriptdaily.com/2017/08/13/hikma-pharmaceuticals-plc-lonhik-rating-reiterated-by-numis-securities-ltd.html.
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.